Form 4: EyePoint Pharmaceuticals CFO Reports Stock Transaction
Insider Transaction (Form 4)
George Elston, Chief Financial Officer of EyePoint Pharmaceuticals, Inc., reported multiple transactions in common stock on August 20, 2026.
Summary
- Other acquisition/disposition: disposed of 5,000 Common Stock on August 20, 2026; holds 25,000 after (Indirect).
- Other acquisition/disposition: acquired 5,000 Common Stock on August 20, 2026; holds 96,691 after (Direct).
- Bona fide gift: disposed of 64,953 Common Stock on August 20, 2026; holds 32,517 after (Direct).
- Bona fide gift: acquired 64,953 Common Stock on August 20, 2026; holds 64,953 after (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
George Elston — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-20 | Other acquisition/disposition | Common Stock | 5,000 | — | — | 25,000 |
| 2026-08-20 | Other acquisition/disposition | Common Stock | 5,000 | — | — | 96,691 |
| 2026-08-20 | Bona fide gift | Common Stock | 64,953 | — | — | 32,517 |
| 2026-08-20 | Bona fide gift | Common Stock | 64,953 | — | — | 64,953 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-20 | Other acquisition/disposition (5,000 shares) |
| 2026-08-20 | Other acquisition/disposition (5,000 shares) |
| 2026-08-20 | Bona fide gift (64,953 shares) |
| 2026-08-20 | Bona fide gift (64,953 shares) |
Keywords
insider transaction, Form 4, EYPT, EyePoint, Inc., neutral, George Elston
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.